Phase 2 Hormone Receptor-Positive Breast Cancer Clinical Trials
13 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–13 of 13 trials
Recruiting
Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 2
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Triple-Negative Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor-Positive Breast Carcinoma+1 more
Laura Huppert, MD, BA36 enrolled1 locationNCT06224673
Recruiting
Phase 2
Study of Screening Brain MRIs in Stage IV Breast Cancer
Triple-Negative Breast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute170 enrolled2 locationsNCT05115474
Recruiting
Phase 1Phase 2
VS-6766+Abema+Fulv in Met HR+/HER- BC
Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Adrienne G. Waks63 enrolled3 locationsNCT05608252
Recruiting
Phase 2
ETHAN - ET for Male BC
Hormone Receptor-Positive Breast CancerMale Breast CancerHormone Receptor-Negative Breast Carcinoma
Jose Pablo Leone60 enrolled8 locationsNCT05501704
Recruiting
Phase 2
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
HER2-negative Breast CancerHormone Receptor-Positive Breast CancerLocoregional Recurrence
Oana Danciu200 enrolled20 locationsNCT05467891
Recruiting
Phase 1Phase 2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Metastatic Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Ellipses Pharma95 enrolled14 locationsNCT05573126
Recruiting
Phase 2
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+1 more
University of California, Irvine20 enrolled1 locationNCT05524584
Recruiting
Phase 2
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
HER2-negative Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Hormone Receptor-Positive Breast Cancer+3 more
Peking University People's Hospital393 enrolled1 locationNCT06970912
Recruiting
Phase 2
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
HER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
Rutgers, The State University of New Jersey40 enrolled7 locationsNCT06518837
Recruiting
Phase 2
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O.75 enrolled3 locationsNCT06263543
Recruiting
Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Breast CancerTriple-Negative Breast CancerBreast Cancer Female+8 more
Baylor Breast Care Center185 enrolled2 locationsNCT05020860
Recruiting
Phase 2
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Breast CancerHormone Receptor-Positive Breast CancerHormone Therapy
National Taiwan University Hospital60 enrolled2 locationsNCT05766410